In 2024, Robert A. Bradway earned $2.58M in total compensation at Amgen, primarily from $1.87M salary. Most recently acquired 11,988 shares in May 2024. Currently holds stock worth $171.35M. Has donated $63.30M in stock to charitable causes. Has led Amgen for over 13 years.
Compensation History
Annual executive compensation data for Robert A. Bradway, including salary, bonuses, and stock awards.
Year
2024
Total Compensation
$2.58M
Salary
$1.87M
Bonus
$0.00
Other
$714.33K
Salary
$1.87MBoard Justification
Our executive compensation program is designed to achieve the following objectives: •Pay for performance in a manner that strongly aligns with stockholder interests by rewarding both our short- and long-term performance. •Drive our business strategy by positioning our staff to execute on our strategic priorities in the near- and longer-term with a mix of incentives and targets (financial and operational) that are tied to near- and long-term performance periods and activities. •Attract, motivate, and retain the highest level of talent by providing competitive compensation, consistent with their roles and responsibilities, our success, and their contributions to this success. •Mitigate compensation risk by maintaining pay practices that reward actions and outcomes consistent with the sound operation of our Company and with the creation of long-term stockholder value. •Consider all Amgen staff members in the design of our executive compensation program to ensure a consistent approach that encourages and rewards all staff members who contribute to our success.
Bonus
$0.00Board Justification
N/A
Other Compensation
$714.33KBoard Justification
Other expenses include: (a)Company contributions to non-profit charities designated by the executive in the amount of $10,000 for Messrs. Bradway, Gordon, and Griffith; (b)Executive physicals; and (c)Personal transportation costs for Dr. Bradner related to travel between his home in Massachusetts and the Company's Thousand Oaks headquarters per his offer letter by commercial aircraft or via chartered aircraft using a service agreement with a private aviation provider we were required to assume in connection with our acquisition of Horizon Therapeutics plc (now known as Horizon Therapeutics Limited) and based on actual amounts charged for these flights as well as related ground transportation and lodging costs.
Restricted Stock
Board Justification
N/A
Performance Metrics
•Non-GAAP earnings per share (EPS)•Non-GAAP return on invested capital (ROIC)•Total shareholder return (TSR) relative to that of the S&P 500•Revenues •Non-GAAP net income•Pipeline, clinical study, and regulatory goals•Sustainability and integration goals
Robert A. Bradway
CEO of Amgen
Education
Bachelor's degree in Economics from Amherst College and an MBA from the Wharton School of the University of Pennsylvania.
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
Born
July 19, 1962 - 63 years ago
CEO of Amgen for
13 years 6 months (May 2012 - Present)
Previous Experience
Executive Vice President and Chief Financial Officer at Amgen
Other Amgen CEOs
Holdings
Track Robert A. Bradway's stock holdings and portfolio value over time.
Total Stock Sold
$6.32M
$6.32M
42,000 AMGN shares
What if they kept their stock?
If Robert A. Bradway didn't sell their stock, today they would have:
Extra AMGN42,000 shares worth $14.29M.
This is 126.23% and $7.98M more than what they got when they sold the stock.
Charitable Transactions
186,000 shares
AMGN
Recent Charitable Transactions
186,000 shares
AMGN
Dec 2, 2024
Charity
Insider Trading
Robert A. Bradway's recent stock transactions, purchases, and sales filed with the SEC.
186,000 shares
AMGN
Dec 2, 2024
Charity
90,000 shares
AMGN
Dec 2, 2024
Charity
11,988 shares
AMGN
May 7, 2024
Received
41,133 shares
AMGN
Mar 6, 2024
Received
13,486 shares
AMGN
May 2, 2023
Received
27,915 shares
AMGN
Mar 6, 2023
Received
13,781 shares
AMGN
May 2, 2022
Received
34,964 shares
AMGN
Mar 1, 2022
Received
13,280 shares
AMGN
Apr 30, 2021
Received
38,953 shares
AMGN
Mar 2, 2021
Received
Rivals
Compare Robert A. Bradway with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Daniel O'Day
CEO of Gilead Sciences
2024 Compensation
Stock
$18.79M
Salary
$1.77M
Bonus
$0.00
Other
$1.34M
Total Holdings
$23.48M
Robert M. Davis
CEO of Merck & Co.
2024 Compensation
Stock
$18.10M
Salary
$1.62M
Bonus
$0.00
Other
$561.11K
Total Holdings
$43.45M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M
Christopher Boerner
CEO of Bristol-Myers Squibb
2023 Compensation
Stock
$0.00
Salary
$1.50M
Bonus
$0.00
Other
$311.64K
Total Holdings
$7.39M